ESSEX BIO-TECH Issues Profit Warning, Anticipates Approximately 30% Drop in Interim Profit

Stock News
07/17

The company has announced that for the six-month period ending June 30, 2026, it expects both revenue and profit to decline compared to the same period in 2025.

Revenue is projected to decrease by approximately 10%, and profit is anticipated to fall by around 30% relative to the prior year's figures of about HK$877 million in revenue and HK$163 million in profit.

The primary reason cited for this expected downturn is an increase in the value-added tax borne by the group following the implementation of a new VAT law in China.

Despite these challenges, the company states that it maintains robust cash flow and a solid financial position sufficient to meet its operational requirements.

As of June 30, 2026, the group's cash and cash equivalents stood at approximately HK$807 million.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10